KLRK1 and neoplasm: Of note, we observed that both [CD20×NKG2D#3] and [CD20×NKG2D#32] bibodies enhanced NK cell-mediated ADCC of tumor specific mAbs - promoting the “dual-dual-targeting” concept, which we already proposed in the context of NKG2D-specific immunoligands (33).